Literature DB >> 30603643

Retrospective study on the effects of the prognosis of patients treated with extracorporeal membrane oxygenation combined with continuous renal replacement therapy.

Ping He1, Shixin Zhang1, Bingyang Hu2, Wei Wu1.   

Abstract

BACKGROUND: Patients undergoing extracorporeal membrane oxygenation (ECMO) treatment often have severe fluid overload and electrolyte imbalances and may even suffer acute kidney injury (AKI). It is often necessary to use continuous renal replacement therapy (CRRT). In this study, we aimed to retrospectively analyze the prognosis of patients treated with ECMO combined with CRRT and to find the independent factors that affect the survival rate.
METHODS: There were 32 patients who were treated with ECMO combined with CRRT in our hospital from January 2007 to December 2017 who were analyzed. All of the patients were divided into a survival group and death group. The clinical indicators and biochemical indexes of the two groups were observed, and their differences were compared. Multivariate logistic regression analysis was carried out to determine the independent risk factors.
RESULTS: The fluid balance at ECMO day 3, SOFA score and lactate at CRRT initiation, sequential organ failure assessment (SOFA) score at ECMO weaning, CRRT duration, ECMO to CRRT interval, mechanical ventilation (MV) duration, length of ICU, and overall hospital length of stay were statistically significant (P<0.05). The clinical biochemical indexes at CRRT initiation and ECMO weaning [serum creatinine, pH, white blood cell (WBC), hemoglobin (Hb), bilirubin]; patient's age, gender and BMI; and the fluid balance at ECMO days 1 and 7 were not statistically significance (P>0.05). The fluid balance at ECMO day 3 and lactate at CRRT initiation by multivariable logistic regression analysis were independent risk factors affecting patient prognosis.
CONCLUSIONS: The fluid balance at ECMO day 3 and lactate at CRRT initiation are the prognosis independent risk factors for ECMO + CRRT patients.

Entities:  

Keywords:  Extracorporeal membrane oxygenation (ECMO); continuous renal replacement therapy (CRRT); prognosis

Year:  2018        PMID: 30603643      PMCID: PMC6312806          DOI: 10.21037/atm.2018.11.12

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  22 in total

1.  Recovery of renal function and survival after continuous renal replacement therapy during extracorporeal membrane oxygenation.

Authors:  Matthew L Paden; Barry L Warshaw; Micheal L Heard; James D Fortenberry
Journal:  Pediatr Crit Care Med       Date:  2011-03       Impact factor: 3.624

2.  Neutrophil gelatinase-associated lipocalin levels during extracorporeal membrane oxygenation in critically ill children with congenital heart disease: preliminary experience.

Authors:  Zaccaria Ricci; Stefano Morelli; Isabella Favia; Cristiana Garisto; Gianluca Brancaccio; Sergio Picardo
Journal:  Pediatr Crit Care Med       Date:  2012-01       Impact factor: 3.624

3.  Prognostic factors for adult patients receiving extracorporeal membrane oxygenation as mechanical circulatory support--a 14-year experience at a medical center.

Authors:  Chinchun Lan; Pi-Ru Tsai; Yih-Sharng Chen; Wen-Je Ko
Journal:  Artif Organs       Date:  2010-02       Impact factor: 3.094

4.  Five-year results of 121 consecutive patients treated with extracorporeal membrane oxygenation at Fu Wai Hospital.

Authors:  Feilong Hei; Song Lou; Jingwen Li; Kun Yu; Jinping Liu; Zhengyi Feng; Ju Zhao; Shengshou Hu; Jianping Xu; Qian Chang; Yinglong Liu; Xu Wang; Ping Liu; Cun Long
Journal:  Artif Organs       Date:  2011-02-14       Impact factor: 3.094

5.  Weight-based determination of fluid overload status and mortality in pediatric intensive care unit patients requiring continuous renal replacement therapy.

Authors:  David T Selewski; Timothy T Cornell; Rebecca M Lombel; Neal B Blatt; Yong Y Han; Theresa Mottes; Mallika Kommareddi; David B Kershaw; Thomas P Shanley; Michael Heung
Journal:  Intensive Care Med       Date:  2011-04-30       Impact factor: 17.440

6.  Enhanced fluid management with continuous venovenous hemofiltration in pediatric respiratory failure patients receiving extracorporeal membrane oxygenation support.

Authors:  Nancy G Hoover; Michael Heard; Christopher Reid; Scott Wagoner; Kristine Rogers; Jason Foland; Matthew L Paden; James D Fortenberry
Journal:  Intensive Care Med       Date:  2008-07-15       Impact factor: 17.440

7.  Extracellular fluid and total body water changes in neonates undergoing extracorporeal membrane oxygenation.

Authors:  H L Anderson; A G Coran; R A Drongowski; H J Ha; R H Bartlett
Journal:  J Pediatr Surg       Date:  1992-08       Impact factor: 2.545

8.  Impact of preexisting organ dysfunction on extracorporeal life support for non-postcardiotomy cardiopulmonary failure.

Authors:  Meng-Yu Wu; Pyng-Jing Lin; Feng-Chang Tsai; Yoa-Kuang Haung; Kuo-Sheng Liu; Feng-Chun Tsai
Journal:  Resuscitation       Date:  2008-07-09       Impact factor: 5.262

9.  Significance of hemolysis on extracorporeal life support after cardiac surgery in children.

Authors:  Rasheed Gbadegesin; Shuang Zhao; John Charpie; Patrick D Brophy; William E Smoyer; Jen-Jar Lin
Journal:  Pediatr Nephrol       Date:  2008-11-12       Impact factor: 3.714

10.  Haemofiltration in newborns treated with extracorporeal membrane oxygenation: a case-comparison study.

Authors:  Karin Blijdorp; Karlien Cransberg; Enno D Wildschut; Saskia J Gischler; Robert Jan Houmes; Eric D Wolff; Dick Tibboel
Journal:  Crit Care       Date:  2009-04-03       Impact factor: 9.097

View more
  2 in total

Review 1.  Continuous renal replacement therapy in patients treated with extracorporeal membrane oxygenation.

Authors:  David T Selewski; Keith M Wille
Journal:  Semin Dial       Date:  2021-03-25       Impact factor: 2.886

2.  Impact of CRRT in Patients with PARDS Treated with VV-ECMO.

Authors:  Sébastien Redant; Océane Barbance; Ashita Tolwani; Xavier Beretta-Piccoli; Jacques Massaut; David De Bels; Fabio S Taccone; Patrick M Honoré; Dominique Biarent
Journal:  Membranes (Basel)       Date:  2021-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.